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INTRODUCTION
Demographic study predict that by the year 2020,
postmenopausal women will constitute 17.3% of the
adult population.1 With this ageing population, more
postmenopausal women are presenting for routine
medical care including screening for cervical cancer.
Cervical cytology (Pap Smear) as screening tool
face some significant problems and pitfalls when per-
formed to postmenopausal women. The atrophic
changes in the genital tract of postmenopausal women
may result in cellular changes falsely interpreted as
precancerous lesion and can lead to substantial diffi-
culty in recognizing dyskaryotic cells.2 We reported
six cases of postmenopausal women during a 2 years
periode (2008-2009) who were referred to colposcopy
clinic in Dr. Cipto Mangunkusumo hospital due to
abnormal cervical cytology, 2 of them with smear re-
port of ASCUS, 1 with LSIL, and 3 with HSIL. All
women had atrophic portio and unsatisfactory col-
poscopies. After 10-14 days administration of oral es-
trogen, cervical smear showed benign cellular changes
due to atrophy with inflammation. Colposcopy finding
showed low grade CIN on 4 women, while the others
remain unsatisfactory. The biopsy confirmed cervisi-
tis on all women.
The false information given to the patient will re-
sult in psychological, financial burden, and overtreat-
ment of surgery.
Abstract
Objective: To determine the most effective dose of estradiol
valerat (daily oral administration of 1 mg or 2 mg for 14 days) to
improve squamous epithel maturation of Pap Smear on post-
menopausal women.
Method: Seventy one postmenopausal women with atrophic Pap
Smear were participated in this randomized double blind clinical
trial. 35 subjects received estradiol valerat 1 mg and the other 36
subjects received estradiol valerat 2 mg. After daily oral administra-
tion of estradiol valerat for 14 days, second Pap Smear were per-
formed to evaluate epithel maturation. The side effects were also
evaluated in this study.
Result: There were 5 subjects whom lost to follow up due to re-
fused to perform second Pap Smear and 1 subject was drop out due
to nausea. 65 subjects were included in final analysis. Estradiol
valerat 2 mg was significantly more effective than estradiol valerat
1 mg in improving epithel maturation of Pap Smear preparation on
postmenopausal women. There were no complain about nausea and
vaginal bleeding. Leukorhea occurred more frequently in the 2 mg
group.
Conclusion: Daily oral administration of 2 mg estradiol valerat
was more effective than estradiol valerat 1 mg in improving
squamous epithel maturation of Pap Smear on postmenopausal
women with minimal side effect (leukorhea).
[Indones J Obstet Gynecol 2010; 34-2: 89-91]
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Abstrak
Tujuan: Menentukan dosis estradiol valerat (1 mg atau 2 mg
per oral tiap hari selama 14 hari) yang paling efektif untuk me-
ningkatkan maturasi epitel skuamosa sediaan tes Pap pada perem-
puan pascamenopause.
Metode: Uji klinis tersamar ganda dengan randomisasi ini me-
libatkan 71 perempuan pascamenopause yang hasil tes Papnya
menunjukkan gambaran atrofi. 35 subjek mendapatkan estradiol
valerat 1 mg dan sisanya (36 subjek) mendapatkan estradiol valerat
2 mg. Pasca pemberian estradiol valerat per oral selama 14 hari,
dilakukan tes Pap ulang untuk menilai peningkatan maturasi epitel
dan dinilai efek samping obat.
 Hasil: Tercatat 5 subjek lost to follow up karena menolak tes
Pap ulang dan 1 subjek drop out karena merasa sangat mual de-
ngan obat yang diberikan. Terdapat 65 subjek yang dimasukkan
dalam analisis akhir. Estradiol valerat 2 mg secara bermakna lebih
efektif meningkatkan maturasi epitel skuamosa sediaan tes Pap
pada perempuan pascamenopause dibandingkan estradiol valerat 1
mg. Tidak terdapat keluhan mual atau perdarahan per vaginam.
Leukorhea lebih banyak terjadi secara bermakna pada kelompok
dosis estradiol valerat 2 mg.
Kesimpulan: Estradiol valerat 2 mg per oral tiap hari selama
14 hari lebih efektif dibandingkan dosis 1 mg untuk meningkatkan
maturasi epitel skuamosa sediaan tes Pap pada perempuan pas-
camenopause dengan efek samping minimal berupa leukorhea.
[Maj Obstet Ginekol Indones 2010; 34-2: 89-91]
Kata kunci: tes Pap, perempuan pascamenopause, estradiol va-
lerat, maturasi epitel sediaan tes Pap
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Since there are some significant problems and pit-
falls of cervical cytology in postmenopausal women,
we recommended to all health providers who per-
formed screening to be aware of the atrophic changes.
Cytologist and colposcopist should be aware too, and
do not in haste judging a woman without concerning
the menopause factor. The atrophic changes can be
temporarily reserved by short-term administration of
estrogen which can improve squamous epithel matu-
ration of Pap Smear preparation on postmenopausal
women and increase the acuracy of Pap Smear.
Some study mentioned that estrogen administration
could improve genital tract atrophic condition and as-
sist the interpretation of Pap Smear on postmeno-
pausal women.2-8 But there is still no standard of
preparat and dose of estrogen which effective to im-
prove squamous epithel maturation. That is why in
this study we compare the effectivity of two dose of
estradiol valerat (Progynova® 1 mg and 2 mg) in im-
proving squamous epithel maturation of Pap Smear
preparation on postmenopausal women.
METHODS
The study was conducted from December 2009 to
January 2010 at Pisangan, Jatinegara and Dr. Cipto
Mangunkusumo Hospital. The study population were
all postmenopausal women at Jakarta at the time the
research perfomed. Subjects were recruited by con-
secutive sampling method, who fullfill inclusion cri-
teria age less than 65 years old, willing involved in
this study and exclusion criteria Pap Smear prepara-
tion did not show athrophic smear, diagnosed cervical
cancer and precancerous lesion, using hormonal
drugs, have history of endometrium and breast malig-
nancy, have history of cerebrovascular and coronary
disesase, chronic liver disease, and using tuberculosis
drugs. This study had also been approved by the uni-
versity of Indonesia ethical commission.
Seventy one postmenopausal women with atrophic
Pap Smear participated in this randomized double
blind clinical trial. At the first visit, we assessed clini-
cal appearance of the portio and sensation of pain du-
ring inspeculo insertion was also noted. We divided
sample into two groups by simple random sampling.
35 subjects received estradiol valerat (Progynova®) 1
mg and the remaining 36 subjects received estradiol
valerat 2 mg. After daily oral administration of estra-
diol valerat for 14 days, second Pap Smear were per-
formed to evaluate epithel maturation. We also evalu-
ate the side effects, clinical appearance of the portio
and sensation of pain when inspeculo performed.
Cytology assessment were performed by two ex-
perienced cytologist at the laboratory of cytology at
Dr. Cipto Mangunkusumo Hospital.
RESULTS
There were 5 subjects whom lost to follow up due to
refusal to perform second Pap Smear and 1 subject
was drop out due to nausea. 65 subjects were included
in final analysis. Subjects had a mean age of 54 years
(range: 46-64 years). The majority were housewife
(60%) and had education level at highschool (40%).
Mean parity were 3 (range: 0-8) and mean post-
menopausal period were 5 years (range: 1-21 years).
We found that not all postmenopausal women had
athropic portio. 4.6% of the subjects still showed
squamo-clumnar junction at the portio. All of the first
Pap Smear preparation showed inflammatory back-
ground, but only one preparat specified as inadequate
specimen.
Estradiol valerat 1 mg had effectivity of 84.4% and
estradiol valerat 2 mg 100% to improving epithel
maturation of Pap Smear on postmenopausal women.
Estradiol valerat 2 mg was significantly more effec-
tive than estradiol valerat 1 mg (p: 0.024). (Table 1)
Table 1. Bivariat analysis of estradiol valerat dose with epithel
maturation improvement.
Dose of
Estradiol
Valerat
Epithel Matura-
tion Improve
Epithel Maturation
Not Improve p
n % n %
1 mg 27 84.4 5 7.7 0.024
2 mg 33 100 0 0
Other factors which influence quality of Pap Smear
preparation are specimen adequation and inflamatory
background. On the second Pap Smear, 28% subjects
from the dose group of 1 mg and 39% subjects from
the dose group of 2 mg showed improvement of in-
flammatory background. The difference between two
group was not significant in improving inflammatory
background of Pap Smear preparation (p: 0.337). (Ta-
ble 2).
Table 2. Bivariat analysis of estradiol valerat dose with im-
provement of inflammation background on Pap
Smear preparation
Dose of
Estradiol
Valerat
Inflammation Background on
Pap Smear Preparation After
Administration of Estradiol Valerat
pInflammation + Inflammation -
n % n %
1 mg 23 72 9 28 0.337
2 mg 20 61 13 39
There was no complain about nausea and vaginal
bleeding. But, we had one subject who drop out due
to nausea, this subject had gastritis as predisposing
factor. Leukorhea occurred more frequently in the 2
mg group (p: 0.011). (Table 3)
Table 3. Bivariat analysis of estradiol valerat dose with
leukorhea
Dose of Estra-
diol Valerat
Leukorhea No Leukorhea p
n % n %
1 mg 26 81.25 6 18.75 0.011
2 mg 33 100 0 0
We noted five subjects who lost to follow up. The
concern of lost to follow initially was due to the side
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effect which eventually may affect our final analysis.
However, after interview with those subjects, we
found out that the reason was the pain while in-
speculo, it made them afraid to perform second Pap
Smear. The pain during inspeculo is an important fac-
tor that influence compliance and comfort of the
women in performing Pap Smear. About 92% subjects
felt uncomfortable and pain during inspeculo at the
first Pap Smear, that was due to atrophic vaginitis.
But after 14 days administration of estradiol valerat
all subjects have no complain of pain during inspeculo
because of the leukorhea.
DISCUSSION
Estradiol valerat was proven effective to improve
squamous epithel maturation of Pap Smear prepara-
tion on postmenopausal women. By statistical analy-
sis in this study, 2 mg dose significantly more effec-
tive than 1 mg dose with same administration periode.
Some study mentioned benefit of estrogen admini-
stration on postmenopausal women to improve quality
of epithel of genital and urinary tract. Main objective
of these studies are to manage the signs and symp-
toms of urogenital atrophy.4,8 Other studies tried to
find benefit of estrogen to allow easy differentiation
of areas of dysplasia from the normal mucosa on
colposcopy view.3,5,6
There has not been any study which directly find
estrogen benefit to improve squamous epithel matu-
ration of Pap Smear preparation on postmenopausal
women. Marx P8 used CEE 0.3 mg for 16 weeks for
managing atrophic vaginitis and there was highly sig-
nificant increase in Vaginal Maturation Index com-
pared to placebo treatment.
This study use estradiol valerat because estradiol
valerat is group of natural estrogen with high biology
activity. It has less effect on endometrial proliferation.
Other reasons were drug availability in the market and
there were two doses available which are 1 and 2 mg.
Most of studies used conjugated equin estrogen to
find benefit of estrogen administration on postmeno-
pausal women. There were two preparation, topical
and oral estrogen. The topical preparation could be
better in term of its less systemic effect. However due
to drug availability and consideration of simplicity
and comfort of oral preparation we decided to choose
oral preparation. It will influence patient compliance
to take the medicine.
The duration of administration for 14 days in this
study was quite effective to improve epithel matura-
tion. But if we want the effect of eversion of trans-
formation zone in order to get satisfactory colposcopy
finding, it seem that we will need longer duration of
estrogen administration. Galhardo4 used CEE 0.625
mg for 3 months to improve epithel quality of genital
tract. Marx P8 used CEE 0.3 mg for 16 weeks to ma-
nage atrophic vaginitis. A study from Japan used CEE
1.25 mg for 14 days to allow easy differentiation of
areas of dysplasia from the normal mucosa on col-
poscopy.6 Spitzer7 used topical estrogen for 2-3
weeks to achieve the same effect.
There were no side effect nausea and vaginal
bleeding on the subject that we analyzed. But patient
complained about leukorhea which was not comfort-
able, and this occured more frequent on 2 mg dose
and it statistically significant. Marx P8 found that on
the administration of CEE 0.3 mg for 16 weeks, leu-
korhea was the most common complain. In our study,
lekorhea occured on 81.25% subject of dose 1 mg
group and 100% subject of dose 2 mg group.
On the other side leukorhea had benefit to resolve
pain during inspeculo, and it will influence the com-
pliance and comfort of postmenopausal women in per-
forming Pap Smear.
Estrogen administration can cause nausea, vaginal
bleeding due to endometrium hyperplasia, and leu-
korhea. The incident of side effect will vary depend
on the dose and duration of administration.
On this study we did not find nausea and vaginal
bleeding. But we noted 1 subject who dropped out
due to heavy nausea. After evaluation, we found that
this subject had predispose factor of gastritis and ran-
domly she was on the 2 mg dose. But in this study
the correlation between history of gastritis and nausea
effect after estrogen administration can not be analyzed.
Vaginal bleeding did not occur because the administra-
tion duration was only 14 days, and estradiol valerat
has low proliferative effect on the endometrium.
CONCLUSION
Daily oral administration of 2 mg estradiol valerat
was more effective than estradiol valerat 1 mg in im-
proving squamous epithel maturation of Pap Smear
on postmenopausal women with minimal side effect
(leukorhea).
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